Pramipexole
Pramipexole is a dopamine agonist used primarily to treat Parkinson's disease and restless legs syndrome. It works by stimulating dopamine receptors in the brain, particularly the D3 receptor subtype, to help control movement and reduce symptoms like tremors, stiffness, and the urge to move legs at rest.
Pramipexole is a dopamine agonist that treats Parkinson's disease and restless legs syndrome by stimulating dopamine receptors.
Key facts at a glance
- ATC
- N04BC05
- RxNorm
- 746741
- Generic
- Pramipexole
- Class
- atc-n04
- Brands
- Mirapex
- Availability
- rx
- Lactation
- unknown
- Routes
- oral
- Forms
- tablet
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 1.5mg three times daily
- Maximum
- consult physician
- Frequency
- every 8 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- not approved for pediatric use
- Maximum
- consult physician
- Frequency
- n/a
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 0.125mg three times daily
- Maximum
- consult physician
- Frequency
- every 8 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
8 groupspregnancy
first trimesteravoid if possible
avoid use during pregnancy unless benefits clearly outweigh risks
regular fetal monitoring and ultrasound assessments
Use of this medication in this population requires careful consideration of risks and benefits.
pregnancy
third trimesteravoid if possible
discontinue before delivery when possible; monitor for neonatal withdrawal symptoms
fetal monitoring, assess for signs of withdrawal in newborn
Use of this medication in this population requires careful consideration of risks and benefits.
lactation
breastfeedingdiscontinue breastfeeding
do not use pramipexole while breastfeeding; drug is excreted in human milk
not applicable
Use of this medication in this population requires careful consideration of risks and benefits.
pediatric_age
children under 18not established
not approved for use in pediatric populations; safety and efficacy not established
not applicable
geriatric
elderly over 65start at lowest dose and titrate slowly
use reduced initial dose; monitor for orthostatic hypotension and sedation; increased risk of hallucinations
regular blood pressure monitoring, assess for confusion or hallucinations
Use with caution and monitor for adverse effects.
renal_impairment
severe renal impairmentreduce dose significantly
in severe renal impairment (CrCl <30 mL/min), reduce maximum daily dose to 1.5 mg; consider further reduction in end-stage renal disease
monitor renal function regularly, adjust dose based on creatinine clearance
Use with caution and monitor for adverse effects.
renal_impairment
moderate renal impairmentreduce dose
in moderate renal impairment (CrCl 30-50 mL/min), reduce starting dose and titrate more slowly
monitor renal function every 3-6 months
Use with caution and monitor for adverse effects.
hepatic_impairment
mild to moderateno specific adjustment needed
use with caution; pramipexole is minimally metabolized by liver but hepatic dysfunction may affect pharmacokinetics
monitor liver function tests periodically
Use with caution and monitor for adverse effects.
Statistics and clinical data
Drug class
Pharmacological classification based on mechanism of action
FDA approval year
Initial FDA approval for Parkinson's disease
Common therapeutic uses
Approved indications for pramipexole dihydrochloride
Mechanism of action
Primary pharmacodynamic mechanism
Pramipexole is FDA-approved for treating the signs and symptoms of idiopathic Parkinson's disease, both as initial therapy and as adjunct therapy. It is also indicated for moderate to severe restless legs syndrome.
As a non-ergot dopamine agonist, pramipexole binds with high affinity to D3 receptors and with moderate affinity to D2 and D4 receptor subtypes. By directly stimulating these dopamine receptors, it mimics dopamine's effects in the brain, helping to restore dopaminergic function and improve motor control.
Pramipexole may cause drowsiness, including sudden sleep attacks, and has been associated with impulse control problems such as gambling, eating, or shopping. It should be discontinued gradually to avoid withdrawal symptoms. Patients should be monitored for hallucinations, hypotension, and dyskinesia, particularly when used as adjunct therapy.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy